###begin article-title 0
###xml 98 103 98 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BEST1</italic>
###xml 67 75 <span type="species:ncbi:9606">patients</span>
Functional and clinical data of Best vitelliform macular dystrophy patients with mutations in the BEST1 gene
###end article-title 0
###begin title 1
Purpose
###end title 1
###begin p 2
###xml 115 120 115 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BEST1</italic>
###xml 84 92 <span type="species:ncbi:9606">patients</span>
To analyze functional and clinical data of Best vitelliform macular dystrophy (VMD) patients with mutations in the BEST1 gene.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 23 28 23 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BEST1</italic>
###xml 252 257 252 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BEST1</italic>
###xml 9 17 <span type="species:ncbi:9606">patients</span>
Best VMD patients with BEST1 mutations were evaluated prospectively regarding age, age of onset, best-corrected visual acuity (BCVA), fundus autofluorescence, fluorescein angiography, optical coherence tomography, and electro-oculography. Mutations in BEST1 were established by direct sequencing.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 108 113 108 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BEST1</italic>
###xml 533 538 533 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BEST1</italic>
###xml 21 29 <span type="species:ncbi:9606">patients</span>
###xml 175 183 <span type="species:ncbi:9606">patients</span>
###xml 497 505 <span type="species:ncbi:9606">patients</span>
###xml 597 605 <span type="species:ncbi:9606">patients</span>
###xml 655 663 <span type="species:ncbi:9606">patients</span>
###xml 711 719 <span type="species:ncbi:9606">patients</span>
###xml 874 882 <span type="species:ncbi:9606">patients</span>
###xml 976 984 <span type="species:ncbi:9606">patients</span>
###xml 1024 1032 <span type="species:ncbi:9606">patients</span>
###xml 1038 1046 <span type="species:ncbi:9606">patients</span>
###xml 1095 1103 <span type="species:ncbi:9606">patients</span>
###xml 1183 1191 <span type="species:ncbi:9606">patients</span>
###xml 1436 1444 <span type="species:ncbi:9606">patients</span>
Forty-six eyes of 23 patients (10 male, 13 female) were included in the study. We identified nine different BEST1 mutations (3/9 novel), in ten unrelated families. The age of patients ranged between 3 and 75 years; age of onset varied between 2 and 67 years. BCVA ranged between 20/20 and 20/200. On the basis of fundus biomicroscopy with direct illumination, using one widely accepted classification, the macular lesions could be counted as follows: 1. no lesion (normal fovea): eight eyes, five patients carrying a mutation on the BEST1 gene; 2. previtelliform lesions: six eyes, three affected patients; 3. vitelliform lesions: four eyes, two affected patients; 4. pseudohypopyon: three eyes, three affected patients; 5. vitelliruptive lesions (scrambled egg aspect with dispersion of the vitelliform material without sign of atrophy or fibrosis): ten eyes, six affected patients; 6. atrophic lesions (atrophy with or without residual dispersed material): seven eyes, five patients; 7. fibrotic lesions: eight eyes, five patients. Two patients presented unilateral Best VMD. Both eyes of two patients presented multifocal Best VMD features on fundus examination. Six eyes of four patients have been treated for choroidal neovascularization by thermic photocoagulation [one eye], photodynamic therapy [three eyes], and intravitreal ranibizumab injection [two eyes]. Comparison of interfamilial and intrafamilial clinical data between patients did not reveal differences in age, BCVA, and stage of the disease as evaluated by fundus autofluorescence, fluorescein angiography, and optical coherence tomography (p>0.05). Mean BCVA impairment showed a statistically significant correlation to a more advanced stage of the disease (p<0.001).
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BEST1</italic>
###xml 106 114 <span type="species:ncbi:9606">patients</span>
BEST1 mutations were not correlated with the severity of the functional and clinical data in the Best VMD patients examined.
###end p 8
###begin title 9
Introduction
###end title 9
###begin p 10
###xml 179 180 179 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
###xml 341 346 341 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BEST1</italic>
###xml 412 413 412 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r2">2</xref>
###xml 450 455 450 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BEST1</italic>
###xml 482 483 482 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r3">3</xref>
###xml 613 615 613 615 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 628 629 628 629 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 640 641 640 641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 687 692 687 692 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BEST1</italic>
###xml 1018 1019 1018 1019 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r5">5</xref>
###xml 1048 1053 1048 1053 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BEST1</italic>
Vitelliform macular dystrophy (VMD) was first described by Friedrich Best in 1905 with a complete description of the various stages of the disease from eight related individuals [1]. VMD (OMIM ), also called Best disease, has an autosomal dominant pattern of inheritance but with variable expressivity. The gene involved in Best VMD, called BEST1, has been mapped on chromosome 11q12-q13, cloned, and sequenced [2]. The 68-kDa protein encoded by the BEST1 gene, named bestrophin-1 [3], is localized to the basolateral plasma membrane of the retinal pigment epithelium (RPE) and appears to exhibit properties of Ca2+-activated Cl- channels [4]. More than 100 disease-causing mutations in BEST1 have been reported (), with nearly all of those causing Best VMD affecting single amino acids at one of 66 different positions in bestrophin-1. The onset of Best VMD is variable, having a bimodal distribution with one maximum peak before puberty and a second following puberty and extending through the fifth decade of life [5]. Heterozygous mutations in BEST1 may also cause the adult form of VMD, autosomal recessive bestrophinopathies, other autosomal dominant bestrophinopathies, and rare vitreoretinochoroidopathy.
###end p 10
###begin p 11
###xml 258 259 258 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r6">6</xref>
###xml 260 261 260 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
###xml 375 376 375 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 958 961 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
Best VMD is a clinically heterogeneous and pleomorphic disease; usually it begins with symptoms of metamorphopsia, blurred vision, and a decrease of central vision. Most cases have a solitary lesion in the macula; others have multifocal vitelliform lesions [6,7], which are mostly confined to the posterior pole. Five stages have been described, based on fundus examination [8]: the previtelliform stage (normal macula or subtle RPE alterations), the vitelliform stage (well circumscribed 0.5- to 2-disc-diameter "egg-yolk" lesion), the pseudohypopyon stage (the yellow material accumulated inferiorly), the vitelliruptive stage (partial resorption of the material, scrambled-egg lesion), and the atrophic stage (final macular atrophy). An aspect of fibrosis (elevated changes from white to yellowish) can also be observed as an optional way of evolution of VMD. This cicatricial aspect can appear with or without occurrence of choroidal neovascularization (CNV). There is a controversy about the chronological order of the stages. According to some authors, the sequence of the pseudohypopion/vitelliruptive stages may be reversed.
###end p 11
###begin p 12
###xml 34 35 34 35 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 36 38 36 38 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r10">10</xref>
###xml 173 175 171 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
###xml 248 250 246 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r12">12</xref>
###xml 302 303 300 301 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 501 503 499 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 759 761 757 759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r14">14</xref>
###xml 762 764 760 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
Abnormal electro-oculogram (EOG) [9,10], with a reduced or nondetectable light-peak to dark-trough ratio (</=1.55), combined with a normal clinical electroretinogram (ERG) [11], a blockage effect by vitelliform material on fluorescein angiography [12], and autofluorescence from the vitelliform lesions7 are helpful for diagnosis. Spaide and associates illustrated by optical coherence tomography (OCT) that the yellow vitelliform accumulates in the subretinal space and on the outer retinal surface [13]. We recently reported on the high-definition spectral domain optical coherence tomography (HD-OCT; OCT 4000 Cirrus; Humphrey-Zeiss, San Leandro, CA) findings in all the progressive stages of the disease, including the previtelliform (preclinical) stage [14,15].
###end p 12
###begin p 13
###xml 172 177 172 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BEST1</italic>
###xml 86 94 <span type="species:ncbi:9606">patients</span>
Our purpose in this study was to analyze the functional and clinical data in Best VMD patients, issuing primarily from one single family, according to the mutations in the BEST1 gene.
###end p 13
###begin title 14
Methods
###end title 14
###begin p 15
###xml 1469 1471 1469 1471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r16">16</xref>
###xml 1472 1474 1472 1474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
###xml 9 17 <span type="species:ncbi:9606">patients</span>
###xml 646 654 <span type="species:ncbi:9606">patients</span>
Best VMD patients and relatives that presented consecutively at the Creteil University Eye Clinic, Creteil, France, and at the Foggia University Eye Clinic, Foggia, Italy were included in this prospective study. The clinical diagnosis, based on one or multiple subfoveal vitelliform lesions in at least one eye, was confirmed by two observers (GQ, EHS). At least one affected individual from each family was diagnosed by both EOG and fundus examination. Informed consent was obtained according to approved protocols of the Paris XII University and Foggia University Institutional Review Boards, in agreement with the Declaration of Helsinki. The patients were evaluated based on age and age of onset (age at initial examination for visual impairment), and all underwent a complete ophthalmologic examination, including assessment of best-corrected visual acuity (BCVA) measured at 4 m with standard Early Treatment Diabetic Retinopathy Study charts, fundus biomicroscopy, color photography of the fundus (Topcon TRC-50 retinal camera, Tokyo, Japan), fundus autofluorescence (FAF) frames (Heidelberg Retina Angiograph II, Heidelberg Engineering, Heidelberg, Germany), and red-free and fluorescein angiography (FA) frames (Topcon TRC-50 retinal camera, Tokyo, Japan; Heidelberg Retina Angiograph II, Heidelberg Engineering). Recordings of EOG and ERG (in selected cases) were done according to the International Society for Clinical Electrophysiology of Vision standard [16,17]. OCT examination was performed with time domain OCT (OCT 3000 Stratus, Humphrey-Zeiss) and spectral domain OCT (HD-OCT, OCT 4000 Cirrus, Humphrey-Zeiss). All scans were positioned within the macular area and throughout the vitelliform lesions, based on color fundus photography and FAF. For each scan the shape and reflectivity of the material, its location, the reflectivity and appearance of the RPE, and retinal changes were specified. The diagnosis of Best VMD was based on the presence of large vitelliform or vitelliruptive lesions and a reduced light rise in the EOG, with or without a positive family history of the disease.
###end p 15
###begin p 16
###xml 48 53 48 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BEST1</italic>
###xml 223 228 223 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BEST1</italic>
###xml 285 292 285 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 1419 1421 1419 1421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 4 12 <span type="species:ncbi:9606">patients</span>
###xml 1360 1365 <span type="species:ncbi:9606">human</span>
All patients were screened for mutations in the BEST1 gene by direct sequencing. Genomic DNA was submitted to standard PCR, using intronic primers designed to flank the coding exons (2-11) and exon-intron boundaries of the BEST1 gene (primer sequences and PCR conditions are listed in Table 1). Amplified products were directly sequenced without preliminary purification using the Big Dye Terminator Cycle Sequencing kit v3.1 (Applied Biosystems, Foster City, CA). Sequenced products were purified by exclusion chromatography (Sephadex G50; Sigma-Aldrich, Saint Louis, MO), submitted to electrophoresis on an ABI 3130 automated sequencer (Applied Biosystems, Foster City, CA), and data were analyzed using Sequencing Analysis v5.2 Software (Applied Biosystems). All exons were screened in all probands. Segregation of the mutations with the disease phenotype was established by using the available family members. The pathogenicity of unreported nucleotide changes was assessed by i) studying 96 unrelated control individuals (control group) matched for origin with no personal or familial history of macular degeneration or retinal dystrophy, and ii) applying the  (Harvard University, Boston, MA) program, which predicts possible impact (benign, possibly damaging, probably damaging or unknown) of an amino acid substitution on the structure and function of human proteins (as previously reported by Ramensky et al. [18]).
###end p 16
###begin title 17
Primer sequences and PCR conditions.
###end title 17
###begin p 18
###xml 166 171 166 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BEST1</italic>
###xml 454 462 <span type="species:ncbi:9606">patients</span>
Statistical analyses were performed using STATA 10 MP (StataCorp LP, College Station, TX) for MacOs X. Serial interfamilial and intrafamilial comparisons of specific BEST1 mutations and expressivity with respect to age, BCVA converted to the logarithm of the minimum angle of resolution (logMAR), and stage of the disease were performed using the ANOVA (ANOVA) test. The chosen level of statistical significance was p<0.05. Of note, most of the Best VMD patients analyzed for this study issued from one single family, and it is probably a major limitation of any statistical analysis to propose a severity scaling.
###end p 18
###begin title 19
Results
###end title 19
###begin title 20
Genetic analysis
###end title 20
###begin p 21
###xml 39 44 39 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BEST1</italic>
###xml 107 115 107 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1">Figure 1</xref>
###xml 217 224 217 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2">Table 2</xref>
###xml 456 464 456 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2">Figure 2</xref>
###xml 681 689 681 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f3">Figure 3</xref>
The screening of the 11 exons encoding BEST1 in ten unrelated families (4/10 from Italy; 6/10 from France; Figure 1) resulted in the identification of nine different missense mutations clustered in exons 2, 4, and 7 (Table 2). Six out of the nine mutations have been previously reported to be common Best VMD mutations (p.A243V, p.R92G, p. R92C, p.T91I, p.R25W, p.V9A). The remaining three changes have not been reported elsewhere (p.T4A, p.G15D, p.I230T; Figure 2) and were absent from 192 control chromosomes. Interspecies Basic Local Alignment Search Tool (BLAST) alignments showed that residues at positions 4, 15, and 230 are conserved in vertebrate and invertebrate species (Figure 3). Simulation for functional changes by a structure homology-based method using the Polyphen program resulted in classifying the p.T4A and p.G15D changes as possibly damaging (position-specific independent counts, PSIC=1.847 and 1.936, respectively, and the p.I230T substitution as probably damaging (I230T; PSIC=2.181).
###end p 21
###begin p 22
Pedigrees of the families studied and segregation of the VMD2 mutant alleles. White circles represent unaffected females, filled circles affected females, white squares unaffected males, and filled squares affected males. Deceased individuals are shown with a slanting line across the symbol.
###end p 22
###begin title 23
###xml 42 47 42 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BEST1</italic>
Summary of clinical findings and probands BEST1 mutations.
###end title 23
###begin p 24
###xml 150 153 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
Abbreviations: M represents male; F represents female; RE represents right eye; LE represents left eye; BCVA represents best corrected visual acuity; CNV represents choroidal neovascularization.
###end p 24
###begin p 25
###xml 37 42 37 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BEST1</italic>
Electropherograms of the three novel BEST1 mutations. These electrophoregrams show an heterozygous peak GA at position 44 responsible for a p.G15D mutation in family FG IV, an heterozygous peak TC at position 791 responsible for a p.I230T mutation in family CT II, and an heteozygous peak AG at position 10 responsible for a p.T4A mutation in family CT IV.
###end p 25
###begin p 26
###xml 105 110 <span type="species:ncbi:9606">human</span>
###xml 349 354 <span type="species:ncbi:9606">human</span>
###xml 557 562 <span type="species:ncbi:9606">human</span>
###xml 704 709 <span type="species:ncbi:9606">human</span>
###xml 828 833 <span type="species:ncbi:9606">human</span>
Protein sequence alignments via Protein Basic Local Alignment Search Tool (BLASTP) of the regions of the human proteins of the BEST family (BEST1-4) and of the BEST1 proteins containing the p.T4A, p.G15D, and p.I230T novel mutations. The residues at position 4, 15, and 230 are highly conserved from mammals to flies as well as in two-thirds of the human BEST proteins. Interestingly, when nonconserved, the amino acids are replaced by residues of the same classes (neutral polar threonine at position 4 is changed to neutral polar asparagine and serine in human BEST4 and worm BEST1 proteins, respectively; nonpolar uncharged glycine at position 15 is changed to uncharged nonpolar phenylalanine in the human BEST3 and worm BEST1 sequences, respectively; neutral nonpolar isoleucine at position 230 is changed to valine in the human BEST3 and worm BEST1 proteins). Interestingly, the three novel BEST1 mutations reported here are expected to change the polarity and/or the charge of the protein. The p.T4A mutation changes a polar to a nonpolar amino acid, while the p.G15D and I230T mutations change nonpolar uncharged residues to polar acidic (aspartic acid) and neutral nonpolar (threonine) residues, respectively.
###end p 26
###begin p 27
###xml 338 343 338 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BEST1</italic>
###xml 775 783 775 783 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f4">Figure 4</xref>
###xml 95 103 <span type="species:ncbi:9606">patients</span>
###xml 182 189 <span type="species:ncbi:9606">patient</span>
###xml 744 752 <span type="species:ncbi:9606">patients</span>
Segregation analyses were performed when possible. In all families but one, available affected patients were shown to be heterozygous for the mutation. In family FGIII, the affected patient FG08 was apparently homozygous for the p.R92C mutation. Parental DNA samples were unavailable to determine between homozygosity and deletion at the BEST1 locus. This apparently homozygous p.R92C finding could clearly be homozygous or could reflect a combination between a point mutation in one allele and a deletion in the other allele. However, homozygosity is probable as both parents were born in the same village of the Puglia region in Italy. Finally, that three unaffected individuals harbored the pathogenic mutation identified in their families (patients FG04, FG05, and FG10; Figure 4).
###end p 27
###begin p 28
###xml 240 241 240 241 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 254 255 254 255 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">)</bold>
###xml 322 323 322 323 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 500 501 500 501 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 538 539 538 539 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 95 102 <span type="species:ncbi:9606">patient</span>
###xml 109 116 <span type="species:ncbi:9606">patient</span>
###xml 126 133 <span type="species:ncbi:9606">patient</span>
###xml 226 233 <span type="species:ncbi:9606">patient</span>
###xml 486 493 <span type="species:ncbi:9606">patient</span>
###xml 524 531 <span type="species:ncbi:9606">patient</span>
Spectral domain high-definition optical coherence tomography and electro-oculogram findings of patient FG10, patient FG05 and patient FG04. Spectral domain high-definition optical coherence tomography scan of the right eye of patient FG10 (A, upper panel) shows normal macular findings. Electro-oculogram of the same eye (A, bottom panel) shows the light-peak saccade not uniform, being the light-peak to dark-trough ratio overall normal (>1.55). Electro-oculograms of the right eye of patient FG05 (B), and of the left eye patient FG04 (C), show normal light-peak to dark-trough ratio (>1.55).
###end p 28
###begin p 29
###xml 178 185 <span type="species:ncbi:9606">patient</span>
###xml 195 202 <span type="species:ncbi:9606">patient</span>
###xml 243 250 <span type="species:ncbi:9606">patient</span>
###xml 276 283 <span type="species:ncbi:9606">patient</span>
Finally, our data add another example of amino acid residues that produce Best VMD when mutated to different amino acids: arginine at position 92 was substituted by a glycine in patient FG06 and patient FG07 (FAMILY FG II) or by a cysteine in patient FG08 (FAMILY FG III) and patient CT01 (FAMILY CT I).
###end p 29
###begin title 30
Functional and clinical data
###end title 30
###begin p 31
###xml 45 50 45 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BEST1</italic>
###xml 175 182 175 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 26 34 <span type="species:ncbi:9606">patients</span>
###xml 201 209 <span type="species:ncbi:9606">patients</span>
###xml 361 369 <span type="species:ncbi:9606">patients</span>
###xml 413 421 <span type="species:ncbi:9606">patients</span>
We examined 46 eyes of 23 patients harboring BEST1 mutations (10 male, 13 female). Eighteen had Best VMD, two presented with multifocal Best VMD, and three were asymptomatic (Table 1). The mean age of patients was 27.30 +/-20.09 years. Age of onset varied between 2 and 67 years (median=13.5). BCVA ranged between 20/20 and 20/200 (median, 20/35). All affected patients had bilateral lesions except two unrelated patients who had a unilateral lesion (CT07 aged 27 years and CT05 aged 70 years).
###end p 31
###begin p 32
###xml 299 304 299 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BEST1</italic>
###xml 263 271 <span type="species:ncbi:9606">patients</span>
###xml 363 371 <span type="species:ncbi:9606">patients</span>
###xml 421 429 <span type="species:ncbi:9606">patients</span>
###xml 477 485 <span type="species:ncbi:9606">patients</span>
###xml 640 648 <span type="species:ncbi:9606">patients</span>
###xml 742 750 <span type="species:ncbi:9606">patients</span>
###xml 790 798 <span type="species:ncbi:9606">patients</span>
On the basis of fundus biomicroscopy with direct illumination (performed by two expert retinal physicians [G.Q., E.H.S.]) and using one widely accepted classification, the macular lesions could be counted as follows: 1. no lesion (normal fovea): eight eyes, five patients carrying a mutation on the BEST1 gene; 2. previtelliform lesions: six eyes, three affected patients; 3. vitelliform lesions: four eyes, two affected patients; 4. pseudohypopyon: three eyes, three affected patients; 5. vitelliruptive lesions (scrambled egg aspect with dispersion of the vitelliform material without sign of atrophy or fibrosis): ten eyes, six affected patients; 6. atrophic lesions (atrophy with or without residual dispersed material): seven eyes, five patients; 7. fibrotic lesions: eight eyes, five patients.
###end p 32
###begin p 33
Early stage lesions were characterized by the accumulation of yellowish material within the macula and within and/or outside the macular area, giving an aspect of foveal granularity (previtelliform lesions) or a typical well circumscribed yellow "egg yolk" (vitelliform lesion). This material was highly autofluorescent. On OCT scans it appeared as a hyper-reflective dome-shaped lesion located between the hyporeflective outer nuclear layer and the hyper-reflective RPE layer.
###end p 33
###begin p 34
Later stages included pseudohypopyon and vitelliruptive (scrambled egg aspect with dispersion of the vitelliform material without sign of atrophy or fibrosis) lesions that were characterized by partial/complete resorption of the yellowish material, which was replaced by a fluid component showing no increased fluorescence on FAF and reflectivity on OCT examination. These stages were characterized by loss of continuity and centrifugal and downward movement of the lipofuscin-like material.
###end p 34
###begin p 35
###xml 145 148 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
Late lesions were characterized by partial/complete atrophy (with or without residual dispersed material) or fibrosis (with no detectable active CNV) within the area previously occupied by the yellowish material. FA showed both masking effects, from accumulation of material, and transmission defects, from resorption of material, with passive leakage. The EOG showed an abnormal light-peak to dark-trough ratio (<1.55) in all affected eyes.
###end p 35
###begin p 36
###xml 304 311 <span type="species:ncbi:9606">patient</span>
###xml 334 341 <span type="species:ncbi:9606">patient</span>
###xml 428 435 <span type="species:ncbi:9606">patient</span>
###xml 525 532 <span type="species:ncbi:9606">patient</span>
Even with the same mutation, the age of onset and the disease progression (stage of the disease and visual function) were highly variable interfamilially and intrafamilially. The heterozygous p.R92G and p.G15D mutations accounted for the earliest disease manifestations in our series (at 2 years of age, patient FG07, FAMILY FGII and patient FG09, FAMILY FG IV, respectively) or either a later onset (at the age of 11 years for patient FG06, FAMILY FGII [p.R92G]) or even no disease manifestation (at the age of 30 years for patient FG10 FAMILY FG IV [p.G15D]), respectively.
###end p 36
###begin p 37
###xml 92 95 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 307 310 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
On the other hand, the heterozygous p.R92G, p.R92C, p.T91I, and p.T4A mutations resulted in CNV development (which was treated by photodynamic therapy [both eyes of FG06, right eye of CT01], intravitreal ranibizumab injection [left eye of CT01, right eye of CT06], and thermic photocoagulation [extrafoveal CNV, left eye of CT08]).
###end p 37
###begin p 38
###xml 35 40 35 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BEST1</italic>
###xml 197 205 <span type="species:ncbi:9606">patients</span>
###xml 373 380 <span type="species:ncbi:9606">Patient</span>
###xml 450 457 <span type="species:ncbi:9606">patient</span>
Three cases harboring heterozygous BEST1 mutations in two families showed normal fundus findings, OCT, and EOG (FG04 and FG05 [p.A243V], FAMILY FG I and FG10 [p.G15D], Family FG IV). Two unrelated patients carrying different mutations of exon 2 presented unilateral Best VMD (CT07 [p.T4A, novel mutation] and CT11 [p.R25W] from FAMILY CT IV and FAMILY CT V, respectively). Patient CT03 (FAMILY CTII), heterozygous for the p.I230T novel mutation, and patient FG08 (FAMILY FG III), homozygous or hemizygous for the p.R92G mutation, presented bilateral multifocal Best VMD features on fundus examination.
###end p 38
###begin p 39
###xml 54 59 54 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BEST1</italic>
###xml 593 601 593 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f5">Figure 5</xref>
###xml 715 720 715 720 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BEST1</italic>
###xml 992 997 992 997 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BEST1</italic>
###xml 1246 1248 1246 1248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r14">14</xref>
###xml 1310 1318 1310 1318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f6">Figure 6</xref>
###xml 1323 1331 1323 1331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f7">Figure 7</xref>
###xml 1492 1497 1492 1497 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BEST1</italic>
###xml 1581 1589 1581 1589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f8">Figure 8</xref>
###xml 326 334 <span type="species:ncbi:9606">patients</span>
###xml 341 348 <span type="species:ncbi:9606">Patient</span>
###xml 373 380 <span type="species:ncbi:9606">patient</span>
###xml 614 621 <span type="species:ncbi:9606">patient</span>
###xml 651 658 <span type="species:ncbi:9606">patient</span>
###xml 888 895 <span type="species:ncbi:9606">patient</span>
###xml 1016 1023 <span type="species:ncbi:9606">patient</span>
###xml 1033 1040 <span type="species:ncbi:9606">patient</span>
###xml 1251 1258 <span type="species:ncbi:9606">patient</span>
###xml 1282 1289 <span type="species:ncbi:9606">patient</span>
###xml 1344 1351 <span type="species:ncbi:9606">patient</span>
###xml 1457 1464 <span type="species:ncbi:9606">patient</span>
###xml 1567 1574 <span type="species:ncbi:9606">patient</span>
###xml 1592 1599 <span type="species:ncbi:9606">Patient</span>
No association existed between the specific nature of BEST1 mutations and expressivity in relation to age, BCVA, and stage of the disease, as evaluated by FAF, FA, and OCT (p>0.05). Mean BCVA impairment showed a statistically significant correlation to a more advanced stage of the disease (p<0.001), which was independent of patients' age. Patient FG07 (FAMILY FG II) and patient FG09 (FAMILY FG IV) presented noticeable functional and clinical data in that they were diagnosed at an early age-about 2 years of age with typical vitelliform lesions already visible in funduscopic examination (Figure 5). Moreover, patient FG10 from the same family as patient FG09 (FAMILY FG IV) and harboring the same heterozygous BEST1 mutation, showed normal fundus findings, OCT, and EOG at the age of 30 years. FAMILY FG01 presented noticeable functional and clinical data in that one family member (patient FG03) was diagnosed at a late age (67 years), and two family members with the same heterozygous BEST1 mutation p.A243V (patient FG04 and patient FG05) showed normal fundus findings, OCT, and EOG at the age of 13 and 17 years, respectively. Two unrelated cases presented with the previtelliform stage as diagnosed by fundus examination, EOG, and OCT [14] (patient CT02, Family CT II and patient CT13, Family CT VI; Figure 6 and Figure 7). One case (patient CT03, FAMILY CT II) presented with the multifocal Best VMD features. The other multifocal Best VMD case (patient FG08) carried a homozygous BEST1 mutation (exon 4 p. R92C), the same as the heterozygous one found in patient CT01 (Figure 8). Patient CT07 from FAMILY CT IV (novel mutations, p.T4A) presented an end-stage disease in one eye and no evidence of the disease in the other eye.
###end p 39
###begin p 40
###xml 224 225 224 225 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 245 246 245 246 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 333 334 333 334 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 350 351 350 351 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 576 577 576 577 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 659 660 659 660 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
###xml 99 106 <span type="species:ncbi:9606">patient</span>
###xml 116 123 <span type="species:ncbi:9606">patient</span>
###xml 210 217 <span type="species:ncbi:9606">patient</span>
###xml 231 238 <span type="species:ncbi:9606">patient</span>
###xml 336 343 <span type="species:ncbi:9606">patient</span>
###xml 353 360 <span type="species:ncbi:9606">patient</span>
###xml 579 586 <span type="species:ncbi:9606">patient</span>
###xml 662 669 <span type="species:ncbi:9606">patient</span>
Color fundus photographs, fundus autofluorescence frames and optical coherence tomography scans of patient FG07 and patient FG09. Color fundus photographs shows typical vitelliform lesions within the macula of patient FG07 (A) and patient FG09 (B). These vitelliform lesions appear highly autofluorescent on fundus autofluorescence (C, patient FG07; D, patient FG09), and as hyper-reflective dome-shaped lesions located between the hyporeflective outer nuclear layer and the hyper reflective retinal pigment epithelium layer, on both time domain optical coherence tomography (E, patient FG07) and spectral domain high-definition optical coherence tomography (F, patient FG09) scans.
###end p 40
###begin p 41
###xml 220 221 220 221 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 241 242 241 242 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 549 550 549 550 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 791 792 791 792 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 83 90 <span type="species:ncbi:9606">patient</span>
###xml 100 107 <span type="species:ncbi:9606">patient</span>
###xml 206 213 <span type="species:ncbi:9606">patient</span>
###xml 227 234 <span type="species:ncbi:9606">patient</span>
###xml 355 362 <span type="species:ncbi:9606">patient</span>
###xml 826 833 <span type="species:ncbi:9606">patient</span>
Color fundus photographs and spectral domain optical coherence tomography scans of patient CT02 and patient CT04. A normal fovea and a vitelliruptive macular lesion are shown on color fundus photographs of patient CT02 (A) and patient CT04 (B), respectively. Spectral domain high-definition optical coherence tomography scan shows, in the macular area of patient CT02, a thickening of the layer corresponding to the junction between the retinal pigment epithelium (RPE) and the interface of the inner segment and outer segment of the photoreceptor (C). An optically empty lesion between the RPE and the inner segment /outer segment interface, with clumping of hyper-reflective material on the posterior retinal surface and, on some parts, a hyper-reflective mottling stuck on the RPE layer (D), appears on the macular scan of patient CT04.
###end p 41
###begin p 42
###xml 215 216 215 216 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 236 237 236 237 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 544 545 544 545 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 663 664 663 664 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 83 90 <span type="species:ncbi:9606">patient</span>
###xml 100 107 <span type="species:ncbi:9606">patient</span>
###xml 201 208 <span type="species:ncbi:9606">patient</span>
###xml 222 229 <span type="species:ncbi:9606">patient</span>
###xml 350 357 <span type="species:ncbi:9606">patient</span>
###xml 698 706 <span type="species:ncbi:9606">patients</span>
Color fundus photographs and spectral domain optical coherence tomography scans of patient CT13 and patient CT12. A normal fovea and an atrophic macular lesion are shown on color fundus photographs of patient CT13 (A) and patient CT04 (B), respectively. Spectral domain high-definition optical coherence tomography scan shows, in the macular area of patient CT13, a thickening of the layer corresponding to the junction between the retinal pigment epithelium (RPE) and the interface of the inner segment and outer segment of the photoreceptor (C). A thinning of all the retinal layers with enhancement of reflectivity of RPE, which seems to spread far behind it (D), appears on the macular scan of patients CT12.
###end p 42
###begin p 43
###xml 213 214 213 214 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 380 381 380 381 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 584 585 584 585 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 847 848 847 848 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 1221 1222 1221 1222 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
###xml 115 122 <span type="species:ncbi:9606">patient</span>
###xml 132 139 <span type="species:ncbi:9606">patient</span>
###xml 199 206 <span type="species:ncbi:9606">patient</span>
###xml 366 373 <span type="species:ncbi:9606">patient</span>
###xml 473 480 <span type="species:ncbi:9606">patient</span>
###xml 889 896 <span type="species:ncbi:9606">patient</span>
Color fundus photographs, fundus autofluorescence frames and spectral-domain optical coherence tomography scans of patient CT01 and patient FG08. Color fundus photographs show the fibrotic lesion of patient CT01 (A), characterized by an aspect of macular fibrosis without any detectable active choroidal neovascularization, and the multifocal vitelliform lesions of patient FG08 (B), characterized by a vitelliruptive aspect within the macular area. The fibrotic lesion of patient CT01 is responsible for reduced autofluorescence within the macula, on fundus autofluorescence frames (C), as well as for a prominent hyper reflective thickening at the level of the retinal pigment epithelium (RPE) inducing marked anterior bulging, accompanied by thinning of the sensory retina, on spectral domain high-definition optical coherence tomography scan (E); the multifocal vitelliform lesions of patient FG08 are visualized as multiple hyperautofluorescent lesions, on fundus autofluorescence frames, as well as an optically empty lesion between the RPE and the inner segment/outer segment interface, with clumping of hyper-reflective material on the posterior retinal surface, on time domain optical coherence tomography scan (F).
###end p 43
###begin title 44
Discussion
###end title 44
###begin p 45
###xml 136 138 136 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r19">19</xref>
###xml 139 141 139 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r20">20</xref>
###xml 200 205 200 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BEST1</italic>
###xml 212 213 212 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r3">3</xref>
###xml 338 339 338 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r3">3</xref>
###xml 340 342 340 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r21">21</xref>
###xml 343 345 343 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r22">22</xref>
###xml 389 391 389 391 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 404 405 404 405 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 416 417 416 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 418 420 418 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r23">23</xref>
###xml 421 423 421 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r24">24</xref>
###xml 1062 1064 1062 1064 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
The most determinant symptom of Best VMD is the abnormal EOG with a reduced light-peak to dark-trough ratio combined with a normal ERG [19,20]. Bestrophin 1, the 585-amino acid protein encoded by the BEST1 gene [3], is a member of the RFP-TM family of proteins, so named for their highly conserved arginine, phenylalanine, proline motif [3,21,22], which appears to exhibit properties of Ca2+-activated Cl- channels [4,23,24]. Bestrophin 1 does not appear to be the channel itself but to act as a modulating subunit; thus channel function would directly correlate to the involved mutation. The apparent role of bestrophin 1 in the regulation of ion transport obviously affects the light peak on EOG; it is unlikely that the light peak defect itself is the cause of vision loss in Best VMD. Any connection between the light-peak deficit in Best VMD and lipofuscin accumulation in the RPE (the most common histopathologic finding in Best VMD) is speculative. However, given that ion transport is a requirement for acidification of phagolysosomal compartments and Ca2+ is a critical regulator of vesicle fusion, either of the proposed functions of bestrophin 1, if impaired, could lead to the accumulation of lipofuscin (and ultimately cause vision loss from lipofuscin toxicity to photoreceptors). To date more than 108 different BEST1 mutations have been reported (see the ).
###end p 45
###begin p 46
###xml 232 240 232 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f3">Figure 3</xref>
###xml 336 337 336 337 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 543 545 543 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r25">25</xref>
###xml 649 650 649 650 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Here, we report three novel missense changes absent from 192 control chromosomes. All three affected residues are conserved through evolution and were predicted by a structure homology-based method to have an impact on the protein (Figure 3). Two out of the three mutations occur in exon 2 (p.T4A and p.G15D), which is located in the NH2 cytoplasmic domain of the protein. Interestingly, it has been demonstrated that the p.T6P and p.A10V mutations that affect this domain produce currents with an amplitude >20% that of wild-type bestrophin [25]. The novel mutations p.T4A and p.G15D are predicted to change the polarity and/or the charge of the NH2 terminus of the protein and therefore may be regarded as disease causing. The third novel mutation, p.I230T, may alter the structure of the protein as it changes a hydrophobic residue located in the transmembrane domain of the protein into a polar residue.
###end p 46
###begin p 47
###xml 140 141 140 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r3">3</xref>
Of note, the p.V9A change had previously been classified as a change of uncertain pathogenicity seemingly conservative by Petrukhin et al. [3]. In our study this change was regarded as a disease-causing mutation by virtue of its absence from 192 control chromosomes and its Polyphen PSIC score (1.949), which suggests that it may have a functional impact.
###end p 47
###begin p 48
###xml 26 31 26 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BEST1</italic>
###xml 126 128 126 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r26">26</xref>
###xml 129 131 129 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r27">27</xref>
###xml 256 258 256 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r28">28</xref>
###xml 277 279 277 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r29">29</xref>
###xml 355 360 355 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BEST1</italic>
###xml 529 534 529 534 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BEST1</italic>
###xml 687 692 687 692 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BEST1</italic>
###xml 945 950 945 950 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BEST1</italic>
###xml 1095 1100 1095 1100 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BEST1</italic>
###xml 1367 1369 1367 1369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r29">29</xref>
###xml 1903 1908 1903 1908 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BEST1</italic>
###xml 2081 2083 2081 2083 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r30">30</xref>
###xml 630 638 <span type="species:ncbi:9606">patients</span>
###xml 898 905 <span type="species:ncbi:9606">patient</span>
###xml 995 1002 <span type="species:ncbi:9606">patient</span>
###xml 1222 1229 <span type="species:ncbi:9606">patient</span>
###xml 1359 1365 <span type="species:ncbi:9606">humans</span>
###xml 1409 1416 <span type="species:ncbi:9606">patient</span>
###xml 1653 1660 <span type="species:ncbi:9606">patient</span>
###xml 1758 1761 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
Heterozygous mutations in BEST1, which usually cause typical Best VMD, may also cause adult vitelliform macular degeneration [26,27], autosomal dominant bestrophinopathy, and a rare and unique condition called autosomal dominant vitreoretinochoroidopathy [28]. Burgess et al. [29] recently reported on compound heterozygous or homozygous mutations in the BEST1 gene as the causative mutations for a distinctive retinopathy, which they named autosomal-recessive bestrophinopathy (ARB). Given that the different diseases caused by BEST1 gene mutations may share common clinical findings, a complete clinical examination of Best VMD patients combined with molecular genetics studies of the BEST1 gene is mandatory for adequate counseling of the families. Interestingly, while in nine of the ten pedigrees reported here the disease segregated as an autosomal dominant trait, in one family the affected patient (FG08) was apparently homozygous for a BEST1 mutation [p.R92C]. The common origin of the patient's parents' homozygosity for the mutation is the likely reason, although hemizygosity at the BEST1 locus cannot be excluded. In any case, mutational biallelism raises the question as to whether, instead of Best VMD, the patient may be affected with the autosomal-recessive bestrophinopathy described by Burgess et al. as a null phenotype of bestrophin-1 in humans [29]. Clinical examination showed that the patient had no ARB-associated, scattered, punctate flecks and retinal edema but presented with bilateral multifocal lesions consistent with the diagnosis of multifocal Best VMD. This phenotype may be considered more severe than that of another patient heterozygous for the p.R92C mutation who is affected with bilateral focal lesions complicated by CNV. This observation differs from that of Bakall et al. who reported on the histopathology of a donor eye from an individual homozygous for the BEST1 p.W93C mutation and concluded that the clinical and pathological effects of homozygosity for the p.W93C mutation are not more severe than those reported for heterozygotes [30].
###end p 48
###begin p 49
###xml 207 212 207 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BEST1</italic>
###xml 476 484 <span type="species:ncbi:9606">patients</span>
###xml 617 624 <span type="species:ncbi:9606">patient</span>
In our series we report a large interfamilial and intrafamilial clinical variability in terms of age of onset, disease progression, stage of the lesions, and visual function. We found no association between BEST1 mutations and expressivity, with respect to age, BCVA, and stage of the disease as evaluated by FAF, FA, and OCT. Mean BCVA impairment showed a statistically significant correlation to a more advanced stage of the disease. This association was independent of the patients' age. These data suggest that a functional impairment in Best VMD may be related to the progression of the disease rather than to a patient's age. However, in the current series there was only one family to illustrate the phenotype of each mutation except for one mutation. This probably represents a major limitation of any statistical analysis in proposing a severity scaling.
###end p 49
###begin p 50
###xml 253 255 253 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r31">31</xref>
Interestingly, the p.A243V mutation was found to be associated with late onset in one family of our Best VMD series. This finding is consistent with a previous report of a mild and relatively invariable Best VMD phenotype associated with this mutation [31]. Even though our study was not designed to investigate disease progression, the absence of phenotype in two siblings of the same family harboring the mutation may be explained by their young age (13 and 17 years). However, it is possible that these two individuals may remain unaffected (normal fundus findings, OCT, and EOG) through their life span as well. Incomplete penetrance is indeed a well known feature in BEST1 disease. Functional and clinical data in our series may support this notion. The heterozygous p.R92G an p.G15D mutations resulted in the earliest disease manifestation (at 2 years of age); however, the same mutation was also responsible for either a later onset (at the age of 11 years for FG06 [p.R92G]) or even no disease manifestation (at the age of 30 years for FG10 [p.G15D]) within the same families (FAMILY FG II and FAMILY FG IV, respectively).
###end p 50
###begin p 51
###xml 4 12 <span type="species:ncbi:9606">patients</span>
###xml 59 67 <span type="species:ncbi:9606">patients</span>
###xml 331 338 <span type="species:ncbi:9606">patient</span>
###xml 354 357 <span type="species:ncbi:9606">man</span>
###xml 485 488 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
All patients except two had bilateral macular lesions. Two patients presented with unilateral disease, but this could not be related either to their age or to their genotype. Indeed, one of them, aged 27 (CT07), shared the p.T4A mutation with his 23-year-old sibling presenting with bilateral lesions (CT08). Similarly, the second patient, a 70-year-old man (CT11) carried the p.R25W mutation responsible for bilateral lesions in two of his young relatives, aged 10 and 36. Similarly, CNV did not appear to correlate with the mutation, as suggested by the intrafamilial variability of this trait.
###end p 51
###begin p 52
###xml 108 113 108 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BEST1</italic>
###xml 75 82 <span type="species:ncbi:9606">patient</span>
Bilateral multifocal Best VMD lesions were diagnosed at the age of 41 in a patient heterozygous for another BEST1 mutation, p.I230T. Two younger relatives (aged 9 and 11) presented with an early-stage lesion; progression is uncertain.
###end p 52
###begin p 53
###xml 47 52 47 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BEST1</italic>
###xml 128 130 128 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r27">27</xref>
###xml 131 133 131 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r32">32</xref>
###xml 134 136 134 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r40">40</xref>
###xml 503 505 503 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r30">30</xref>
The wide variability of clinical expression of BEST1 mutations within and between families is consistent with previous reports [27,32-40]. Owing to this wide variability of clinical expression, it is difficult to compare our findings with other previously published series. Moreover, we adopted a widely accepted clinical classification, and, based on fundus biomicroscopy, all eyes were graded as showing only one of the progressive stages of Best VMD; thus, for example, in contrast with Boon et al. [30], we did not consider characteristics attributable to different stages. However, the clinical features reported here for each progressive stage were typical and actually consistent with other Best VMD series.
###end p 53
###begin p 54
###xml 205 213 <span type="species:ncbi:9606">patients</span>
One limitation of the current study was the absence of real co-segregation analysis for the families with novel reported changes. Another limitation was that we did not perform, systematically, ERG in our patients and thus we were not able to distinguish whether an abnormal light rise on EOG would have been due to either photoreceptor or RPE dysfunction.
###end p 54
###begin p 55
###xml 336 341 336 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BEST1</italic>
###xml 66 74 <span type="species:ncbi:9606">patients</span>
###xml 120 128 <span type="species:ncbi:9606">patients</span>
###xml 194 202 <span type="species:ncbi:9606">patients</span>
###xml 235 238 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 312 320 <span type="species:ncbi:9606">patients</span>
Overall in our series, particularities were found in two affected patients showing unilateral Best VMD, in two affected patients showing, in both eyes, multifocal Best VMD, and in four affected patients (six eyes) who were treated for CNV. All these are well known possible features of Best VMD. Three out of 23 patients (13%) with the BEST1 mutation showed normal fundus, OCT, and EOG findings.
###end p 55
###begin p 56
###xml 53 58 53 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BEST1</italic>
In conclusion, variability of clinical expression of BEST1 mutations suggests that cis or trans-acting genetic modifiers may modulate the functional and clinical data.
###end p 56
###begin title 57
Acknowledgments
###end title 57
###begin p 58
We thank Mrs. Joelle Dumas for her help in collecting data.
###end p 58
###begin title 59
References
###end title 59
###begin article-title 60
Ueber eine hereditare Maculaaffektion: beitrage zur Vererbungslehre.
###end article-title 60
###begin article-title 61
Genetic linkage of vitelliform macular degeneration Best's disease to chromosome 11q13.
###end article-title 61
###begin article-title 62
Identification of the gene responsible for Best macular dystrophy.
###end article-title 62
###begin article-title 63
The vitelliform macular dystrophy protein defines a new family of chloride channels.
###end article-title 63
###begin article-title 64
Hereditary maculardegeneration (HMD) in 246 cases traced to one gene-source in central Sweden.
###end article-title 64
###begin article-title 65
###xml 24 32 <span type="species:ncbi:9606">patients</span>
Long-term evaluation of patients with Best's vitelliform dystrophy.
###end article-title 65
###begin article-title 66
Electro-oculography in families with vitelliform dystrophy of the fovea. Detection of the carrier state.
###end article-title 66
###begin article-title 67
Electro-oculography in Best's macular dystrophy.
###end article-title 67
###begin article-title 68
Hereditary vitelliruptive macular degeneration.
###end article-title 68
###begin article-title 69
Best's vitelliform macular dystrophy.
###end article-title 69
###begin article-title 70
Vitelliform macular dystrophy.
###end article-title 70
###begin article-title 71
High definition optical coherence tomography features in vitelliform macular dystrophy.
###end article-title 71
###begin article-title 72
High-resolution spectral domain optical coherence tomography findings in multifocal vitelliform macular dystrophy.
###end article-title 72
###begin article-title 73
Standard for clinical electrooculography.
###end article-title 73
###begin article-title 74
International Society for Clinical Electrophysiology of Vision. Standard for clinical electroretinography (1999 update).
###end article-title 74
###begin article-title 75
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human non-synonymous SNPs: server and survey.
###end article-title 75
###begin article-title 76
Best's vitelliform dystrophy.
###end article-title 76
###begin article-title 77
Electro-oculography in Best's macular dystrophy.
###end article-title 77
###begin article-title 78
Mutations in a novel gene, VMD2, encoding a protein of unknown properties cause juvenile-onset vitelliform macular dystrophy (Best's disease).
###end article-title 78
###begin article-title 79
###xml 12 17 <span type="species:ncbi:9606">human</span>
Three novel human VMD2-like genes are members of the evolutionary highly conserved RFP-TM family.
###end article-title 79
###begin article-title 80
Structure-function analysis of the bestrophin family of anion channels.
###end article-title 80
###begin article-title 81
###xml 28 42 <span type="species:ncbi:8355">Xenopus laevis</span>
Two bestrophins cloned from Xenopus laevis oocytes express Ca(2+)-activated Cl(-) currents.
###end article-title 81
###begin article-title 82
The bestrophin mutation A243V, linked to adult-onset vitelliform macular dystrophy, impairs its chloride channel function.
###end article-title 82
###begin article-title 83
###xml 39 47 <span type="species:ncbi:9606">patients</span>
Evaluation of the Best disease gene in patients with age-related macular degeneration and other maculopathies.
###end article-title 83
###begin article-title 84
Mutations in the VMD2 gene are associated with juvenile-onset vitelliform macular dystrophy (Best disease) and adult vitelliform macular dystrophy but not age-related macular degeneration.
###end article-title 84
###begin article-title 85
Mutations of VMD2 splicing regulators cause nanophthalmos and autosomal dominant vitreoretinochoroidopathy (ADVIRC).
###end article-title 85
###begin article-title 86
###xml 61 67 <span type="species:ncbi:9606">humans</span>
Biallelic mutation of BEST1 causes a distinct retinopathy in humans.
###end article-title 86
###begin article-title 87
Enhanced accumulation of A2E in individuals homozygous or heterozygous for mutations in BEST1 (VMD2).
###end article-title 87
###begin article-title 88
Clinical and molecular genetic analysis of Best vitelliform macular dystrophy.
###end article-title 88
###begin article-title 89
Genotype-phenotype correlation and longitudinal course in ten families with Best vitelliform macular dystrophy.
###end article-title 89
###begin article-title 90
Molecular evidence for non-penetrance in Best's disease.
###end article-title 90
###begin article-title 91
Focus on molecules: bestrophin (Best-1).
###end article-title 91
###begin article-title 92
Late onset is common in best macular dystrophy associated with VMD2 gene mutations.
###end article-title 92
###begin article-title 93
Clinical and genetic heterogeneity in multifocal vitelliform dystrophy.
###end article-title 93
###begin article-title 94
The mutation spectrum of the bestrophin protein-functional implications.
###end article-title 94
###begin article-title 95
Allelic variation in the VMD2 gene in best disease and age-related macular degeneration.
###end article-title 95
###begin article-title 96
###xml 56 63 <span type="species:ncbi:9606">patient</span>
Late development of vitelliform lesions and flecks in a patient with best disease: clinicopathologic correlation.
###end article-title 96
###begin article-title 97
###xml 64 69 <span type="species:ncbi:9606">human</span>
Differential macular and peripheral expression of bestrophin in human eyes and its implication for best disease.
###end article-title 97

